IDRA - Idera Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.5300
+0.0100 (+0.40%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.5200
Open2.5000
Bid0.0000 x 900
Ask0.0000 x 1800
Day's Range2.4700 - 2.6000
52 Week Range2.2500 - 17.1200
Volume275,987
Avg. Volume373,640
Market Cap70.895M
Beta (3Y Monthly)3.19
PE Ratio (TTM)N/A
EPS (TTM)-1.8590
Earnings DateOct 26, 2017 - Oct 30, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.00
Trade prices are not sourced from all markets
  • Idera Pharmaceuticals, Inc. (IDRA) Shares March Higher, Can It Continue?
    Zacks10 days ago

    Idera Pharmaceuticals, Inc. (IDRA) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Idera Pharmaceuticals, Inc. (IDRA).

  • Idera Pharmaceuticals (IDRA) Reports Q1 Loss, Lags Revenue Estimates
    Zacks17 days ago

    Idera Pharmaceuticals (IDRA) Reports Q1 Loss, Lags Revenue Estimates

    Idera (IDRA) delivered earnings and revenue surprises of 13.04% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire18 days ago

    Idera Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

    EXTON, Pa., May 02, 2019 -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the.

  • Will Idera Pharmaceuticals (IDRA) Report Negative Q1 Earnings? What You Should Know
    Zacks19 days ago

    Will Idera Pharmaceuticals (IDRA) Report Negative Q1 Earnings? What You Should Know

    Idera (IDRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Need To Know: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Insiders Have Been Buying Shares
    Simply Wall St.21 days ago

    Need To Know: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Insiders Have Been Buying Shares

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We often see insiders buying up shares in companies that perform well over the long term. On the other...

  • GlobeNewswirelast month

    Idera Pharmaceuticals Provides Corporate Update

    Idera Pharmaceuticals, Inc. (“Idera”) (IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drugs for both oncology and rare disease indications, today announced that Cristina Csimma, Pharm. D., M.H.P. and Michael Dougherty have been appointed to the Board of Directors, effective April 10, 2019.

  • GlobeNewswire2 months ago

    Idera Pharmaceuticals Presents ILLUMINATE-101 Data Demonstrating Tilsotolimod Activates Innate and Adaptive Immunity as Monotherapy in Patients with Refractory Solid Tumors at the American Association for Cancer Research (AACR) 2019 Annual Meeting

    Idera Pharmaceuticals, Inc. (“Idera”) (IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drugs for both oncology and rare disease indications, today is reporting clinical and translational data from the ILLUMINATE-101 Phase 1 study which explored the role of investigational tilsotolimod as monotherapy in patients with various refractory solid tumors. In the poster presentation entitled, “Activation of Innate and Adaptive Immunity Using Intratumoral Tilsotolimod (IMO-2125) as Monotherapy in Patients with Refractory Solid Tumors: a Phase 1b Study (ILLUMINATE-101)” (abstract number 4062), Hani Babiker, M.D., Assistant Professor of Medicine and Associate Director of the Phase 1 Program at the University of Arizona Cancer Center, presented results from this study.

  • Life Sciences Pa. reveals awards for its top CEO, top products and deal of the year
    American City Business Journals2 months ago

    Life Sciences Pa. reveals awards for its top CEO, top products and deal of the year

    Pennsylvania's life sciences industry honored its own Wednesday night as awards where handed out at Life Sciences Pennsylvania's annual dinner. The event at the Pennsylvania Convention Center drew a record crowd of more than 1,300 people. The awards include two named in honor of biotech pioneer's Hubert J. P. Schoemaker, the co-founder of Centocor, and Frank Baldino Jr., the co-founder of Cephalon.

  • If You Had Bought Idera Pharmaceuticals Stock Five Years Ago, You’d Be Sitting On A 94% Loss, Today
    Simply Wall St.2 months ago

    If You Had Bought Idera Pharmaceuticals Stock Five Years Ago, You’d Be Sitting On A 94% Loss, Today

    We're definitely into long term investing, but some companies are simply bad investments over any time frame. We really hate to see fellow investors lose their hard-earned money. Spare aRead More...

  • GlobeNewswire2 months ago

    Idera Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update

    – ILLUMINATE-301 Enrollment on Track for Completion Q4 2019 –– ILLUMINATE-204 Enrollment Complete; Data Anticipated Q4 2019 –– ILLUMINATE-206 Trial Expected to Initiate Q2 2019.

  • GlobeNewswire3 months ago

    Idera Pharmaceuticals Completes Enrollment Into the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment

    Idera Pharmaceuticals, Inc. (IDRA) today announced completion of enrollment into the ongoing phase 2 expansion of the ILLUMINATE-204 trial investigating tilsotolimod, Idera’s intratumorally-delivered toll-like receptor 9 (TLR9) agonist, in combination with ipilimumab (Yervoy®*) in patients with unresectable or metastatic melanoma following failure of PD-1 inhibitor treatment. 52 patients have been dosed in the trial which included two separate patient groups.  The company completed the targeted enrollment of 40 patients in the primary enrollment population, constituting patients who are naïve to prior ipilimumab treatment in the metastatic setting.  This patient population mirrors the enrollment for the ILLUMINATE-301 phase 3 pivotal trial.  The secondary exploratory enrollment population targeted up to 20 patients who had prior ipilimumab treatment in the metastatic setting.

  • Idera acquires Travis CI
    TechCrunch4 months ago

    Idera acquires Travis CI

    Travis CI, the popular Berlin-based open-source continuous integration service, has been acquired by Idera, a company that offers a number of SQL database management and administration tools for both on-premises and cloud applications. The move comes at a time when other continuous integration services, including the likes of Circle CI, seem to be taking market share away from Travis CI. Idera, which itself is owned by private equity firm TA Associates, says that Travis is complementary to its current testing tools business and that the acquisition will benefit its current customers.

  • How Much is Idera Pharmaceuticals, Inc.’s (NASDAQ:IDRA) CEO Getting Paid?
    Simply Wall St.4 months ago

    How Much is Idera Pharmaceuticals, Inc.’s (NASDAQ:IDRA) CEO Getting Paid?

    Vinnie, Vin Milano became the CEO of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) in 2014. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After Read More...

  • GlobeNewswire4 months ago

    Idera Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

    Idera Pharmaceuticals, Inc. (IDRA) today announced that the company will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) at the Westin St. Francis Hotel in San Francisco. An archived version will also be available on the company’s website after the event for 90 days. As a convenience to investors, a copy of the company’s presentation will be posted on the Idera corporate website at 7:30 a.m. Eastern Time on Monday, January 7, 2019.

  • GlobeNewswire5 months ago

    Idera Pharmaceuticals Announces Appointment of Carol A. Schafer to its Board of Directors

    Ms. Schafer is a seasoned financial professional with more than 25 years of experience in investment banking and equity capital markets, as well as corporate finance and business development in the biopharmaceutical sector.  Ms. Schafer most recently served as Vice Chair, Equity Capital Markets at Wells Fargo Securities.  Prior to Wells Fargo, Ms. Schafer served as Vice President of Finance and Business Development at Lexicon Pharmaceuticals.  Earlier in her career, Ms. Schafer served as an Equity Capital Markets Sector Head in her role as a Managing Director at J.P. Morgan.  Ms. Schafer received a B.A. from Boston College and an M.B.A from New York University. “Carol brings a unique set of skills and experience that traverses the financial and corporate biotech landscape and will be incredibly valuable to our board as we continue to advance Idera’s mission to bring forward options for patients suffering from life-threatening diseases and ultimately create long-term shareholder value,” stated James Geraghty, Chairman of Idera’s Board of Directors.

  • ACCESSWIRE5 months ago

    Today's Research Reports on Trending Tickers: Johnson & Johnson and Idera Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / December 17, 2018 / Both Johnson & Johnson and Idera Pharmaceuticals were big losers in Friday’s trading session. J&J tumbled on a Reuters story that alleged it knew about its baby powder having asbestos for decades while Idera announced data from an ongoing phase 2 trial that were actually encouraging. Johnson & Johnson shares were tanking on Friday, on a Retuers story that the company had known for decades that its baby powder has asbestos.

  • GlobeNewswire5 months ago

    Idera Pharmaceuticals Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment

    Idera Pharmaceuticals, Inc. (IDRA) today is presenting data from the ongoing phase 2 expansion of the ILLUMINATE-204 trial investigating tilsotolimod, Idera’s intratumorally-delivered toll-like receptor 9 (TLR9) agonist, in combination with ipilimumab (Yervoy®*).

  • GlobeNewswire5 months ago

    Idera Pharmaceuticals to Provide ILLUMINATE-204 Clinical Data Update on Friday, December 14, 2018

    Idera Pharmaceuticals, Inc. (IDRA), a clinical-stage biopharmaceutical company focused on the development and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs, today announced that it plans to release an update on clinical data from the ongoing Phase 2 trial of the combination of intratumoral tilsotolimod and ipilimumab for unresectable or metastatic melanoma following failure of anti-PD-1 inhibitor treatment prior to the opening of the U.S. financial markets on Friday, December 14, 2018. To participate in the conference call, please dial (844) 882-7837 (domestic) and (574) 990-9824 (international).  The webcast can be accessed live or in archived form in the “Investors” section of the company’s website at www.iderapharma.com.  The company will be posting a slide presentation to the Idera corporate website in the “Investors” section which will be referenced during the conference call.

  • GlobeNewswire5 months ago

    United Parcel Service, Endurance International Group, Idera Pharmaceuticals, Aptevo Therapeutics, and Electro Scientific Industries — Future Expectations, Projections Moving into 2018

    NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Benzinga5 months ago

    The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

    Biotech stocks pulled back in last week. Incidentally, some large-cap biotech stocks were hitting new peaks even amid the sectoral downturn. New molecular entity approval hit a new peak at 55 thus far ...

  • How Many Idera Pharmaceuticals Inc (NASDAQ:IDRA) Shares Do Institutions Own?
    Simply Wall St.6 months ago

    How Many Idera Pharmaceuticals Inc (NASDAQ:IDRA) Shares Do Institutions Own?

    If you want to know who really controls Idera Pharmaceuticals Inc (NASDAQ:IDRA), then you’ll have to look at the makeup of its share registry. Institutions often own shares in more Read More...

  • Idera Pharmaceuticals (IDRA) Reports Q3 Loss, Lags Revenue Estimates
    Zacks6 months ago

    Idera Pharmaceuticals (IDRA) Reports Q3 Loss, Lags Revenue Estimates

    Idera (IDRA) delivered earnings and revenue surprises of 17.86% and -93.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press6 months ago

    Idera: 3Q Earnings Snapshot

    On a per-share basis, the Exton, Pennsylvania-based company said it had a loss of 43 cents. Losses, adjusted for gains related to mergers and acquisitions, were 46 cents per share. The results surpassed ...

  • GlobeNewswire6 months ago

    Idera Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

    –  Company to Provide ILLUMINATE 204 Data Update in the First Half of December 2018 ––  Cash runway into first quarter of 2020 – EXTON, Pa., Nov. 06, 2018 -- Idera.